Pancreatic Adenocarcinoma Clinical Trials in Scottsdale, Arizona

4 studies are recruiting for pancreatic adenocarcinoma in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    5 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07805954 on ClinicalTrials.gov

  2. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Honor Health Research Institute, Scottsdale, Arizona
    Locations
    82 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

  3. Pancreatic Cancer Detection Consortium

    This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Honorhealth, Scottsdale, Arizona
    Locations
    13 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT06388967 on ClinicalTrials.gov

  4. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.